The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

On September 26, the U.S. Food and Drug Administration (FDA) approved a drug called Cobenfy to treat schizophrenia. Cobenfy is a combination of xanomeline and trospium chloride that has a novel ...

AbbVie faces setback as schizophrenia trial for emraclidine fails, but still has potential with other assets from Cerevel.

Cobenfy also contains trospium, which blocks some of the side effects. The most common are nausea, vomiting and indigestion.

BMS also highlighted the FDA approval of Cobenfy, a novel schizophrenia treatment, and positive advancements in oncology, including new registration opportunities. Additionally, BMS acquired ...

BMS also highlighted the FDA approval of Cobenfy, a novel schizophrenia treatment, and positive advancements in oncology, including new registration opportunities. Additionally, BMS acquired Karuna ...

The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...

26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric disorder. Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb ...

Cobenfy, improved disease symptoms with a well-tolerated safety profile over 12 months across two Phase 3 trials. In September, the FDA approved the drug previously known as KarXT as a novel ...

fuelled by robust pipeline progress and the US Food and Drug Administration (FDA) approval of its antipsychotic drug Cobenfy for the treatment of schizophrenia in September 2024. Cobenfy is ...